{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:18:09Z","timestamp":1762309089334,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["ZYGD23020"],"award-info":[{"award-number":["ZYGD23020"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jpba.2025.116834","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T21:42:45Z","timestamp":1742679765000},"page":"116834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Distribution, metabolism, and excretion of [14C] purinostat mesylate, a novel selective HDAC I\/IIb inhibitor, in rats analyzed by high-performance liquid chromatography coupled with LTQ orbitrap mass spectrometry\/radioactivity monitoring"],"prefix":"10.1016","volume":"261","author":[{"given":"Ziyan","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpba.2025.116834_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Invest"},{"issue":"20","key":"10.1016\/j.jpba.2025.116834_bib2","doi-asserted-by":"crossref","first-page":"15066","DOI":"10.3390\/ijms242015066","article-title":"The Roles of Histone Deacetylases in the Regulation of Ovarian Cancer Metastasis","volume":"24","author":"Xu","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.jpba.2025.116834_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"ABPv Kuilenburg. Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"Ruijter","year":"2003","journal-title":"Biochem J."},{"issue":"5","key":"10.1016\/j.jpba.2025.116834_bib4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2011.267","article-title":"Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy","volume":"31","author":"Spiegel","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.jpba.2025.116834_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.jpba.2025.116834_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jpba.2025.116834_bib7","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic mechanisms in breast cancer therapy and resistance","volume":"12","author":"Garcia-Martinez","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.jpba.2025.116834_bib8","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.3390\/ijms23052755","article-title":"Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children","volume":"23","author":"Lejman","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.jpba.2025.116834_bib9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/asheducation-2009.1.578","article-title":"Novel therapies for relapsed myeloma","author":"Stewart","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"12","key":"10.1016\/j.jpba.2025.116834_bib10","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1158\/1078-0432.CCR-08-2787","article-title":"Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications","volume":"15","author":"Schrump","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.jpba.2025.116834_bib11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tcb.2008.04.003","article-title":"HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions","volume":"18","author":"Valenzuela-Fernandez","year":"2008","journal-title":"Trends Cell Biol."},{"issue":"11","key":"10.1016\/j.jpba.2025.116834_bib12","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4155\/fmc.12.80","article-title":"Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives","volume":"4","author":"Giannini","year":"2012","journal-title":"Future Med Chem."},{"issue":"6","key":"10.1016\/j.jpba.2025.116834_bib13","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: Trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"11","key":"10.1016\/j.jpba.2025.116834_bib14","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1021\/acs.jmedchem.6b00579","article-title":"Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities","volume":"59","author":"Chen","year":"2016","journal-title":"J. Med Chem."},{"issue":"24","key":"10.1016\/j.jpba.2025.116834_bib15","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1158\/1078-0432.CCR-19-0516","article-title":"Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL-Induced B-Cell Acute Lymphoblastic Leukemia","volume":"25","author":"Yang","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.jpba.2025.116834_bib16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1517\/13543784.2011.577737","article-title":"Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor","volume":"20","author":"Boumber","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"7","key":"10.1016\/j.jpba.2025.116834_bib17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma","volume":"16","author":"Duvic","year":"2007","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.jpba.2025.116834_bib18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jpba.2025.116834_bib19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol."},{"issue":"13","key":"10.1016\/j.jpba.2025.116834_bib20","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"Belinostat: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jpba.2025.116834_bib21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/07853890.2022.2045347","article-title":"Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model","volume":"54","author":"Zhu","year":"2022","journal-title":"Ann. Med"},{"issue":"3","key":"10.1016\/j.jpba.2025.116834_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s13318-024-00884-6","article-title":"Pharmacokinetic Study of Ultrasmall Superparamagnetic Iron Oxide Nanoparticles HY-088 in Rats","volume":"49","author":"Song","year":"2024","journal-title":"Eur. J. Drug Metab. Pharm."},{"issue":"21","key":"10.1016\/j.jpba.2025.116834_bib23","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.4155\/bio.12.252","article-title":"Bioanalysis of drug in tissue: current status and challenges","volume":"4","author":"Xue","year":"2012","journal-title":"Bioanalysis"},{"issue":"8","key":"10.1016\/j.jpba.2025.116834_bib24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nri1669","article-title":"Structure and function of the spleen","volume":"5","author":"Mebius","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"5940","key":"10.1016\/j.jpba.2025.116834_bib25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1126\/science.1175202","article-title":"Identification of splenic reservoir monocytes and their deployment to inflammatory sites","volume":"325","author":"Swirski","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jpba.2025.116834_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)06642-6","article-title":"Mechanisms of bile formation, hepatic uptake, and biliary excretion","volume":"36","author":"Klaassen","year":"1984","journal-title":"Pharmacol. Rev."},{"issue":"10","key":"10.1016\/j.jpba.2025.116834_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","article-title":"Enterohepatic circulation: physiological, pharmacokinetic and clinical implications","volume":"41","author":"Roberts","year":"2002","journal-title":"Clin. Pharm."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852500175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852500175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:15:52Z","timestamp":1762308952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852500175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":27,"alternative-id":["S073170852500175X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116834","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distribution, metabolism, and excretion of [14C] purinostat mesylate, a novel selective HDAC I\/IIb inhibitor, in rats analyzed by high-performance liquid chromatography coupled with LTQ orbitrap mass spectrometry\/radioactivity monitoring","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116834"}}